Novartis, Par Settle Patent Suit Over Lotrel
Novartis International AG and Par Pharmaceutical Cos. Inc. have moved to dismiss a patent suit over Par's proposed generic version of Novartis' billion-dollar hypertension drug Lotrel....To view the full article, register now.
Already a subscriber? Click here to view full article